Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Koning Health Celebrates Milestone of 150,000 Scans Worldwide


NORCROSS, Ga., March 27, 2024 /PRNewswire/ -- Koning Health, leader in advanced medical imaging technology, is proud to announce a significant milestone in its journey to revolutionize diagnostic imaging. The company has successfully completed 150,000 scans globally, demonstrating the effectiveness and reliability of its innovative imaging solutions.

Since its inception, Koning has been at the forefront of medical imaging technology, continually pushing the boundaries of what is possible. The completion of 150,000 scans is not just a number; it represents countless lives impacted, diagnoses clarified, and treatments optimized. This milestone underscores Koning's commitment to providing top-tier imaging capabilities to healthcare providers and patients around the world.

Experts are taking note of the capabilities presented with Koning Vera Breast CT, including physicians like Dr. David Bodne. Dr. Bodne is an MD Anderson trained Diagnostic Radiologist specializing in breast imaging for the past 30 years and who has a long affiliation with the Piedmont health care system. Dr. Bodne has praised Koning's technology, stating, "the utilization of Koning Vera Breast CT has delivered an increased confidence in both findings and lack of findings." He went on to say, "the interpretive time to read BCT is on par with DBT. Breast CT eliminates the need to compress the breast tissue and this feature alone is something women have been asking about for decades."

Furthermore, Dr. Bodne highlights the superiority of Koning's imaging solutions, remarking, "with the Koning Vera Breast CT, radiologists have a choice to introduce contrast enhanced imaging, especially for women with dense breast tissue where needed. The efficiency of this exam is superior to the time to achieve breast MRI, yet with comparable results. Overall, this technology is revolutionary for both patients and radiologists."

Such endorsements from medical professionals underscore the transformative impact of Koning's technology on the field of diagnostic imaging. As Koning reaches this milestone, the company reaffirms its dedication to innovation, quality, and patient care. With over 150,000 scans completed, Koning continues to set new standards in the medical imaging industry, providing clearer, faster, and more accurate diagnostic information.

Koning is grateful to its dedicated team, healthcare partners, and the patients who trust in its technology. The company looks forward to continuing its mission of improving diagnostic imaging and enhancing patient outcomes worldwide.

About Koning: Koning is a global Health Technology company focused on improving the breast imaging industry with its patented Koning Vera Breast CT (KBCT). Koning's vision is to create a revolution in medical imaging through advanced computed tomography technology that dramatically improves the way clinicians visualize and evaluate breast tissue. The KBCT is expected to optimize early disease detection, diagnosis, intervention, and treatment, and will improve survival rates for millions of patients worldwide. For more information, please visit Koning's website or email Koning at [email protected]

SOURCE KONING CORPORATION


These press releases may also interest you

at 08:30
Toitures Hogue's commitment to providing its employees with a structured, professional working environment that guarantees complete safety in the workplace, both on the job and on the job site, has just been awarded its renewed ISO 45001...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...



News published on and distributed by: